Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC1416 Injection in Moderate to Severe COPD
CTR20260100Phase 2Active
- Sponsor
- Nanjing Rongjiekang
- Start
- Mar 2026
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of RC1416 in chronic obstructive pulmonary disease (COPD), sponsored by Nanjing Rongjiekang. Started Mar 2026; status: active.
02
Drugs
RC1416
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20260100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260100.